Effect of interferonβ and the development of neutralising antibodies, on reactivation of latent EBV, in patients with multiple sclerosis

被引：0
|
作者：
Farrell, Rachel [1 ]
Antony, Dinu [2 ]
Clark, Duncan [3 ]
Garson, Jeremy [4 ]
Miller, David H. [1 ]
Giovannoni, Gavin [2 ]
机构：
[1] Inst Neurol, London WC1N 3BG, England
[2] QMUL, Inst Cell & Mol Sci, London, England
[3] Barts & London NHS Trust, Dept Virol, London, England
[4] UCLH, Dept Virol, London, England
来源：
MULTIPLE SCLEROSIS | 2008年 / 14卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：S229 / S229
页数：1
相关论文
共 50 条
  • [21] Fate of multiple sclerosis patients positive for neutralising antibodies towards interferon beta shifted to alternative treatments
    Malucchi, S
    Capobianco, M
    Gilli, F
    Marnetto, E
    Caldano, M
    Sala, A
    Bertolotto, A
    NEUROLOGICAL SCIENCES, 2005, 26 (Suppl 4) : S213 - S214
  • [22] Frequency and clinical aspect of neutralising antibodies to interferon-beta in a large cohort of multiple sclerosis patients
    Bucello, S.
    Liberatore, G.
    Moiola, L.
    Radaelli, M.
    Sala, A.
    Capobianco, M.
    Bertolotto, A.
    Martinelli, V.
    Comi, G.
    MULTIPLE SCLEROSIS, 2009, 15 (09): : S130 - S130
  • [23] In vivo bioactivity of interferon-beta in multiple sclerosis patients with neutralising antibodies is titre-dependent
    Sominanda, A.
    Hillert, J.
    Fogdell-Hahn, A.
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2008, 79 (01): : 57 - 62
  • [24] Neutralising Antibodies to Interferon-beta Therapy in Chinese Patients with Relapsing and Remitting Multiple Sclerosis.
    Ip, W. K.
    Lau, A. Y. L.
    Zhang, S.
    Au, C. C. K.
    Wong, W.
    Lau, K. K.
    Li, P.
    Chan, E. Y. T.
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 (03) : 416 - 417
  • [25] Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis
    Sorensen, PS
    Ross, C
    Clemmesen, KM
    Bendtzen, K
    Frederiksen, JL
    Jensen, K
    Kristensen, O
    Petersen, T
    Rasmussen, S
    Ravnborg, M
    Stenager, E
    Koch-Henriksen, N
    LANCET, 2003, 362 (9391): : 1184 - 1191
  • [26] Neutralising antibodies to interferon-beta in multiple sclerosis: technical report and validation of a cytopathic effect assay
    Massart, C.
    Oger, J.
    Grossberg, S. E.
    Gibassier, J.
    Le Page, E.
    Edan, G.
    MULTIPLE SCLEROSIS, 2006, 12 : S201 - S201
  • [27] Effect of HLA genotype on the development of neutralizing antibodies to interferon beta in patients with multiple sclerosis
    Lundkvist, M.
    Link, J.
    Fink, K.
    Hermanrud, C.
    Brynedal, B.
    Fogdell-Hahn, A.
    Kockum, I.
    Hillert, J.
    IMMUNOLOGY, 2012, 137 : 663 - 663
  • [28] Development of interferon beta-neutralising antibodies in multiple sclerosis-a systematic review and meta-analysis
    Govindappa, Karthik
    Sathish, Jean
    Park, Kevin
    Kirkham, Jamie
    Pirmohamed, Munir
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2015, 71 (11) : 1287 - 1298
  • [29] Evaluation of anti-interferon beta neutralising antibodies in subjects with relapsing multiple sclerosis
    Farrell, Rachel A.
    Leary, Siobhan
    Rudge, Peter
    Thompson, Alan
    Miller, David
    Giovannoni, Gavin
    NEUROLOGY, 2007, 68 (12) : A117 - A117
  • [30] PRESERVED IN VIVO RESPONSE TO INTERFERON-α IN MULTIPLE SCLEROSIS PATIENTS WITH NEUTRALISING ANTIBODIES AGAINST INTERFERON-β: AN ONGOING CLINICAL TRIAL
    Magyari, M.
    Sondergaard, H. B.
    Sellebjerg, F.
    Sorensen, P. S.
    EUROPEAN JOURNAL OF NEUROLOGY, 2011, 18 : 272 - 272
12345